Co-Diagnostics (CODX) Expands OEM Agreement with Bio Molecular Systems at AACC

Co-Diagnostics, Inc. (Nasdaq: CODX) announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC.

Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.

BMS currently manufactures the magnetic induction PCR instrument that is sold by the Company as the Co-Dx Box™, which includes software that optimized specifically to enhance ease-of-use of the Company's molecular assays. The expanded branding and distribution OEM agreement increases Co-Dx's approved sales territories to 193 countries worldwide.

Company CEO Dwight Egan commented "We are excited for the opportunities that we believe this expanded agreement will provide the Company to increase the reach of our state-of-the-art products. Co-Dx tests have already been sold to laboratories and distributors in over 50 countries, and with this expanded agreement we expect that even more areas will be able to benefit from Co-Dx's high-quality, affordable molecular testing tools."

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• ADT Corp. (ADT) Names Jeff Likosar as Chief Financial Officer
• Nanometrics (NANO) Issues Business Update, Reports FY23 Results